ESTRO Brachytherapy for Prostate Cancer 2018

What is your preferred management for a patient aged 66

years presenting with an IPSS of 19, PSA of 13.6, Gleason

score 4+4 prostate cancer which is stage T3a on MR

staging? He has no significant co-morbidities

A. Radical prostatectomy

B. Active surveillance

C. External beam IMRT to

78Gy with ADT

D. LDR seed brachytherapy

E. External beam IMRT +

HDR boost

– ID:

BT2018